No Data
No Data
Johnson & Johnson Gets FDA Priority Review of Nipocalimab in Generalized Myasthenia Gravis
Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
Wells Fargo Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Maintains Target Price $166
Express News | J&J: Nipocalimab Granted U.S. FDA Priority Review for the Treatment of Generalized Myasthenia Gravis (Gmg)
Express News | Arkuda Therapeutics: J&J Exercised Option to Buy Co's Portfolio of Lysosomal Function Enhancers for Upfront Payment & Extra Milestone Payments
No Data
NoDragonsPlz : so we go to moon?
小羊369 :
104668340 :
71246197 : I’m a beginner. I don’t know what to say or do.
OG Kanaka : Still a good stock to DCA (dollar cost average) in for the long term. You want quantum exposure for your portfolio you can’t go wrong with stocks like $Alphabet-C (GOOG.US)$
Short term, will see plenty volatility as traders want to make money NOW, not later. Look for short term opportunities as a trader. Long term, just keep buying fractionally.
So if you got time on your side, just DCA in general to be on the safer side
View more comments...